Journal of Cancer Research and Clinical Oncology

, Volume 140, Issue 12, pp 2163–2168 | Cite as

IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status

  • Emanuel Adelino M. Damasceno
  • Fabiana Pirani Carneiro
  • Albino Verçosa de Magalhães
  • Marcos de Vasconcelos Carneiro
  • Gustavo Henrique Soares Takano
  • Leonora Maciel de Sousa Vianna
  • Heinrich Bender Kohnert Seidler
  • Tercia Maria Mendes Lousa de Castro
  • Maria Imaculada Muniz-Junqueira
  • Rivadávio Fernandes Batista Amorim
  • Vânia Maria Moraes Ferreira
  • Andrea Barreto Motoyama
Rapid Communication

Abstract

Background

The aim of this study was to evaluate the expression of IMP3, an independent poor prognostic factor for many cancers, and its association with clinicopathological features and HER2 status.

Methods

Gastrectomy specimens from 106 patients were evaluated by immunohistochemistry and fluorescence in situ hybridization.

Results

HER2 overexpression was found in 4.71 % of the samples. A negative association was observed between HER2 overexpression and grade of differentiation. No association was observed between HER2 overexpression and status of surgical margins, vascular invasion, perineural invasion, nodal metastasis and depth of invasion. Among all specimens of gastric cancer, 67.92 % were positive for IMP3. Expression of IMP3 was significantly higher in specimens with vascular invasion, perineural invasion, nodal metastasis and higher depth of invasion. HER2 overexpression was detected in only 5.55 % of IMP3 positive specimens.

Conclusions

IMP3 expression was frequently observed in gastric cancer and was associated with poor prognostic clinicopathological features. A survival benefit with HER2 therapy should be expected for the minority of patients with IMP3 positive specimens. Studies should be conducted to evaluate the response to HER2 therapy of gastric cancer expressing IMP3.

Keywords

HER2 IMP3 Immunohistochemistry FISH Gastric cancer 

References

  1. Bang YJ (2012) Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J Clin Gastroenterol 46(8):637–648PubMedCrossRefGoogle Scholar
  2. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697PubMedCrossRefGoogle Scholar
  3. Beljan Perak R, Durdov MG, Capkun V, Ivcevic V, Pavlovic A, Soljic V, Peric M (2012) IMP3 can predict aggressive behaviour of lung adenocarcinoma. Diagn Pathol 7(1):165PubMedCentralPubMedCrossRefGoogle Scholar
  4. Bell JL, Wächter K, Mühleck B et al (2013) Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cell Mol Life Sci 70(15):2657–2675PubMedCentralPubMedCrossRefGoogle Scholar
  5. Boku N (2014) HER2-positive gastric cancer. Gastric Cancer 17:1–12PubMedCentralPubMedCrossRefGoogle Scholar
  6. Brasil. Ministério da Saúde, Instituto Nacional de Câncer (2011) Estimativa 2012: incidência de câncer no Brasil/Instituto Nacional de Câncer. INCA, Rio de JaneiroGoogle Scholar
  7. Chua TC, Merrett ND (2012) Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes—a systematic review. Int J Cancer 130(12):2845–2856PubMedCrossRefGoogle Scholar
  8. Clauditz TS, Wang CJ, Gontarewicz A, Blessmann M, Tennstedt P, Borgmann K, Tribius S, Sauter G, Dalchow C, Knecht R, Münscher A, Wilczak W (2013) Expression of insulin-like growth factor II mRNA-binding protein 3 in squamous cell carcinomas of the head and neck. J Oral Pathol Med 42(2):125–132PubMedCrossRefGoogle Scholar
  9. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917PubMedCrossRefGoogle Scholar
  10. Gong Y, Woda BA, Jiang Z (2014) Oncofetal protein IMP3, a new cancer biomarker. Adv Anat Pathol 21(3):191–200PubMedCrossRefGoogle Scholar
  11. Grabsch H, Sivakumar S, Gray S et al (2010) HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value—conclusions from 924 cases of two independent series. Cell Oncol 32:57–65PubMedGoogle Scholar
  12. Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523–1529PubMedCrossRefGoogle Scholar
  13. Hechtman JF, Polydorides AD (2012) HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med 136(6):691–697PubMedCrossRefGoogle Scholar
  14. Hofmann M, Stoss O, Shi D et al (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:797–805PubMedCrossRefGoogle Scholar
  15. Hu S, Wu X, Zhou B, Xu Z, Qin J, Lu H, Lv L, Gao Y, Deng L, Yin J, Li G (2014) IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 140(6):883–893PubMedCrossRefGoogle Scholar
  16. Jiang Z, Chu PG, Woda BA, Liu Q, Balaji KC, Rock KL, Wu CL (2008) Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res 14(17):5579–5584PubMedCrossRefGoogle Scholar
  17. Jung JE, Ioshi SO (2013) Immunohistochemical assessment of HER2 expression in gastric cancer in a cohort of 118 Brazilian patients. J Bras Patol Med Lab 49:361–367CrossRefGoogle Scholar
  18. Li S, Cha J, Kim J, Kim KY, Kim HJ, Nam W, Cha IH (2011) Insulin-like growth factor II mRNA-binding protein 3: a novel prognostic biomarker for oral squamous cell carcinoma. Head Neck 33(3):368–374PubMedGoogle Scholar
  19. Liao B, Hu Y, Brewer G (2011) RNA-binding protein insulin-like growth factor mRNA-binding protein 3 (IMP-3) promotes cell survival via insulin-like growth factor II signaling after ionizing radiation. J Biol Chem 286(36):31145–31152PubMedCentralPubMedCrossRefGoogle Scholar
  20. Lin L, Zhang J, Wang Y, Ju W, Ma Y, Li L, Chen L (2013) Insulin-like growth factor-II mRNA-binding protein 3 predicts a poor prognosis for colorectal adenocarcinoma. Oncol Lett 6(3):740–744PubMedCentralPubMedGoogle Scholar
  21. Maresch J, Schoppmann SF, Thallinger CM, Zielinski CC, Hejna M (2012) Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment. Crit Rev Oncol Hematol 82(3):310–322PubMedCrossRefGoogle Scholar
  22. Okada K, Fujiwara Y, Nakamura Y et al (2012) Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma. J Surg Oncol 105(8):780–785PubMedCrossRefGoogle Scholar
  23. Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H (2008) IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol 21(4):431–437PubMedCrossRefGoogle Scholar
  24. Rivera Vargas T, Boudoukha S, Simon A, Souidi M, Cuvellier S, Pinna G, Polesskaya A (2014) Post-transcriptional regulation of cyclins D1, D3 and G1 and proliferation of human cancer cells depend on IMP-3 nuclear localization. Oncogene 33(22):2866–2875PubMedCrossRefGoogle Scholar
  25. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25(5):637–650PubMedCrossRefGoogle Scholar
  26. Samanta S, Pursell B, Mercurio AM (2013) IMP3 protein promotes chemoresistance in breast cancer cells by regulating breast cancer resistance protein (ABCG2) expression. J Biol Chem 288(18):12569–12573PubMedCentralPubMedCrossRefGoogle Scholar
  27. Schaeffer DF, Owen DR, Lim HJ, Buczkowski AK, Chung SW, Scudamore CH, Huntsman DG, Ng SS, Owen DA (2010) Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer 10:59PubMedCentralPubMedCrossRefGoogle Scholar
  28. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182PubMedCrossRefGoogle Scholar
  29. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRefGoogle Scholar
  30. Walter O, Prasad M, Lu S et al (2009) IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol 40(11):1528–1533PubMedCrossRefGoogle Scholar
  31. Wang L, Li HG, Xia ZS, Lü J, Peng TS (2010) IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: a retrospective study. Chin Med J (Engl) 123(24):3554–3558Google Scholar
  32. Won JR, Gao D, Chow C et al (2013) A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. Mod Pathol 26(11):1438–1450PubMedCrossRefGoogle Scholar
  33. Xylinas E, Cha EK, Khani F, Kluth LA, Rieken M, Volkmer BG, Hautmann R, Küfer R, Chen YT, Zerbib M, Rubin MA, Scherr DS, Shariat SF, Robinson BD (2014) Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder. J Urol 191(3):830–841PubMedCrossRefGoogle Scholar
  34. Zilberstein B, Malheiros C, Lourenço LG et al (2013) Brazilian consensus in gastric cancer: guidelines for gastric cancer in ABCD. Arq Bras Cir Dig 26(1):2–6PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Emanuel Adelino M. Damasceno
    • 1
  • Fabiana Pirani Carneiro
    • 1
  • Albino Verçosa de Magalhães
    • 1
  • Marcos de Vasconcelos Carneiro
    • 3
  • Gustavo Henrique Soares Takano
    • 1
  • Leonora Maciel de Sousa Vianna
    • 1
  • Heinrich Bender Kohnert Seidler
    • 2
  • Tercia Maria Mendes Lousa de Castro
    • 2
  • Maria Imaculada Muniz-Junqueira
    • 2
  • Rivadávio Fernandes Batista Amorim
    • 2
  • Vânia Maria Moraes Ferreira
    • 2
  • Andrea Barreto Motoyama
    • 2
  1. 1.Pathological Anatomy CenterUniversity Hospital of Brasilia (UNB)BrasíliaBrazil
  2. 2.Pathology DepartmentBrasília UniversityBrasíliaBrazil
  3. 3.Gastroenterology ServiceArmed Forces Hospital of BrasiliaBrasíliaBrazil

Personalised recommendations